BACKGROUND: Glioblastoma multiforme (GBM) is associated with a poor prognosis, and patients rely heavily on family caregivers for physical and emotional support. The capability and mental health of family caregivers may influence their ability to provide care and affect patient outcomes. The objective of the current study was to investigate whether caregivers' anxiety, depressive symptoms, burden, and mastery influenced survival in a sample of patients newly diagnosed with GBM. METHODS: Baseline data from caregiverpatient dyads participating in a longitudinal study funded by the National Institutes of Health were used. Cox regression analyses were performed to determine whether caregiver anxiety (Profile of Mood States-Anxiety), depressive symptoms (Center for Epidemiologic Studies-Depression Scale), burden (Caregiver Reaction Assessment), and feelings of mastery (Mastery Scale) predicted the survival time of patients with GBM after controlling for known covariates (patient age, Karnofsky performance status, type of surgery, and postsurgical treatment). RESULTS: A total of 88 caregiver-patient dyads were included. The median overall survival for the sample was 14.5 months (range, 0-88 months). After controlling for covariates, caregiver mastery was found to be predictive of patient survival. With each unit increase in mastery, there was a 16.1% risk reduction in patient death (95% confidence interval, 0.771-0.913; P<.001). CONCLUSIONS: To the authors' knowledge, the results of the current study are among the first to explore the impact of family caregiving on the outcomes of patients with GBM. If these results are supported in other studies, providing neuro-oncology caregivers with more structured support and guidance in clinical practice has the potential to improve caregivers' feelings of mastery, thereby influencing patients' well-being for the better. Cancer 2017;123:832-40.
INTRODUCTION
Glioblastoma multiforme (GBM; World Health Organization grade 4) is the most common primary malignant brain tumor diagnosed in adults. 1 This rapidly progressive form of cancer typically is associated with a poor prognosis; the median survival is 15 months.
2 Standard treatment-surgery followed by temozolomide chemotherapy with concomitant radiotherapy-does not have "curative" intent but rather aims at preventing disease recurrence and extending survival while preserving patients' quality of life. 3, 4 Research has shown that younger age, better performance status, unifocal tumor location, degree of surgical resection, any surgical resection as opposed to biopsy only, and postsurgical treatment (radiotherapy/chemotherapy) are among the most important prognostic factors of survival after diagnosis. [5] [6] [7] Moreover, O6-methylguanine-DNA methyltransferase (MGMT) promotor methylation, which is believed to predict response to chemotherapy, 8 is reportedly predictive of longer survival after diagnosis of a GBM. 9, 10 The disease-specific symptom burden that accompanies GBM often includes highly debilitating sequelae such as paresis, sensory loss, visual-perceptual deficits, cognitive deficits, and seizures. 11 Moreover, changes in personality and behavior, 12, 13 fatigue, 14 and depression 15 occur frequently. Patients with GBM typically come to rely on their family caregivers (eg, spouses, adult children, or close friends) for physical and emotional support. Consequently, many family caregivers experience considerable burden and emotional distress. [16] [17] [18] Caregivers' level of mastery, which can be defined as the feeling of being in control of the care situation, can influence the amount of distress perceived by family caregivers. 19, 20 Indeed, mastery has been shown to have a significant effect on the amount of distress reported by the family caregiver as a result of providing care in neuro-oncology, 21 and in other caregiving populations.
Caregivers' emotional health has long been hypothesized to influence the quality of care delivered in the home to patients with chronic illness as well as patient outcomes, yet to the best of our knowledge little data exist to support this hypothesis. One study suggested that unmet needs for symptom management, financial support, or community support in caregivers who provided end-oflife care appeared to influence the quality of care delivered to the patient (eg, professional health care, dignityconserving care, individualized care, and family relationships). 23 In family caregivers caring for an individual with dementia, decreased burden has been associated with delayed institutionalization of the patient, 24 and less psychological distress in caregivers appears to be predictive of better survival in patients with dementia. 25 In community-dwelling elderly care recipients, similar effects of caregiver burden on patient survival have been reported. 26 Cancer caregiving differs from dementia caregiving because the disease presents with a more abrupt onset, and has a more variable disease course. 27 Therefore, the emotional health of caregivers also likely follows a different trajectory, thus affecting patient outcomes differently. Among patients with cancer who are receiving chemotherapy, caregiver distress appears to be negatively associated with patient problems in self-care and activities of daily life. 28 Furthermore, higher levels of depressive symptoms and burden among family caregivers have been associated with a decline in the functional status of patients with breast cancer. 29 Inversely, there are indications that lower levels of caregiver distress are associated with better physical health among patients with advanced cancer. 30 However, to our knowledge, it remains unclear whether caregiver emotional health may influence survival in patients with cancer. This is especially relevant in oncological populations with high caregiver burden and poor disease trajectories, such as patients with GBM.
The neurological and cognitive symptoms experienced by patients with GBM represent unique challenges to their family caregivers. 31 To our knowledge, there have been no studies focusing on how the emotional health of family caregivers influences outcomes in patients with GBM. The purpose of the current study was to examine the impact of several key indicators of caregiver distress (ie, anxiety, depressive symptoms, caregiver burden, and mastery) at the time of GBM diagnosis on patient survival after controlling for known covariates (age, extent of surgical resection, postsurgical treatment, and functional status). Obtaining knowledge regarding whether caregivers' emotional health and distress influence patient survival could provide leads for intervening in and improving both caregiver and patient well-being.
MATERIALS AND METHODS

PARTICIPANTS
Caregiver-patient dyads were recruited to participate in a large, longitudinal study of biobehavioral interactions in neuro-oncology caregivers (National Cancer Institute grant RO1CA118711). Recruitment procedures have been described in more detail elsewhere. 32 Dyads were recruited within 3 months of the patient's initial diagnosis from a National Cancer Institute-designated cancer center. Caregiver eligibility criteria were: 1) aged 21 years; 2) able to read and speak English; 3) identified by patients as the primary, nonprofessional, nonpaid individual who provided the majority of emotional, financial, and/or physical support; and 4) not currently a primary caregiver for anyone else other than children aged <21 years. Patient eligibility criteria were: 1) aged 21 years; 2) diagnosed (verified via pathology) with a primary malignant brain tumor within 3 months; and 3) able to read and speak English. Both members of the dyad had to consent to participate for the other to be included. A total of 228 dyads were approached; 164 agreed to participate. The most common reasons for nonconsent (64 dyads) were "lack of interest" (52%) and "feeling overwhelmed" (33%). For the current analyses, only patients with World Health Organization grade 4 GBM and their caregivers were included (54% of the sample; N 5 88 dyads). Participants were recruited between October 2005 and March 2012.
Procedure and Outcome Measures
Assessments took place within 3 months of the patient's diagnosis (baseline), and at 4 months, 8 months, and 12 months. The baseline caregiver assessment was used as a potential predictor of patients' time to death. This was done because shortly after diagnosis, the emotional health of caregivers is not as heavily influenced by the individual patient's disease trajectory, which can vary greatly from patient to patient despite the uniform GBM diagnosis. Clinical data were obtained from the patient's medical records and verified with the neuroradiologist or neurooncologist if questions arose. Caregiver data were obtained by a trained research assistant who conducted structured interviews in person or via telephone to ensure completeness. Care recipient functional status, along with the other covariates, was obtained via in-person interviews and medical record review. The Institutional Review Board approved the study protocol and all participants provided written informed consent.
Outcome measures
Caregivers' depressive symptoms were assessed with the shortened 10-item version of the Center for Epidemiologic Studies-Depression Scale (a 5 .88; N 5 88). 33, 34 The participant's experience of depressive symptoms is rated on a 4-point scale. Scores range between 0 and 30, with higher scores indicating higher levels of depression. Based on trajectory modeling analyses in the same longitudinal study, the cutoff score for being at risk of major clinical depression was set at 8.
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Anxiety was measured using the shortened version of the Profile of Mood States-Anxiety questionnaire (a 5 .92; N 5 86). 35 The caregiver's experience of feeling "on edge," "nervous," and "tense" are evaluated on a 5-point scale, with higher scores indicating more anxiety.
Three constructs of caregiver burden were measured by the Caregiver Reaction Assessment 36 : the impact of providing care on caregivers' self-esteem (a 5 .84; N 5 31), on feelings of abandonment (a 5 .82; N 5 36), and on disruptions in caregivers' schedules (a 5 .76; N 5 82). A higher score on the self-esteem scale indicates better self-esteem, whereas higher scores on the 2 other scales indicate greater caregiver burden. The original study protocol did not include the items comprising the self-esteem and abandonment scales; these were added after participant recruitment was initiated because it was believed these could add valuable information regarding caregiver burden. As a result, there were increased missing values.
Caregivers' feelings of mastery were assessed with the Mastery Scale (N 5 83). 37 On a scale ranging from 1 (indicating strongly disagree) to 4 (indicating strongly agree), caregivers' perception of control over the care situation was evaluated. Eight items were used to calculate the total mastery score (a 5 .62). Higher scores indicate higher levels of perceived control.
The date of the patient's diagnosis was defined as the date of the surgery (N 5 88). Date of death was collected by medical record review and/or by checking obituaries through October 2015 (N 5 88). Five patients first underwent surgery at a different hospital, and therefore the exact date of diagnosis was missing. Herein, the date of study entry (<3 months after diagnosis) was used to calculate survival time.
Patient performance status was measured with the Karnofsky performance status (KPS) scale, 38 as detailed in the clinical notes (N 5 85). If available, data regarding other factors known to influence survival such as MGMT methylation status were obtained through medical record review (N 5 36). These data were not collected routinely in the clinic during the first years of the study (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) , yielding many missing values.
Patients' symptom severity was assessed using 28 items of the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT; N 5 66). 39 Symptom severity is scored on a scale from 0 (indicating not present) to 10 (indicating as bad as you can imagine). An average score was calculated per patient to represent overall symptom severity (a 5 .89). Missing values also were due to the questions being added to the protocol after participant recruitment had started because it was believed this would provide valuable information regarding symptom severity.
Statistical Analyses
All statistical analyses were performed with SPSS statistical software (version 22.0; IBM Corporation, Armonk, NY). Descriptive statistics were used to report sociodemographic and clinical characteristics. To compare caregivers with and without assessment of caregiver burden (self-esteem and abandonment scales) in terms of age, sex, educational level (years of education), and relationship with the patient (spouse or other), Student t tests and chi-square tests were performed. Multiple imputation techniques (5 rounds) were used if < 10% of the data for a given predictor or covariate were missing and missingness was determined to be at random (anxiety, caregiver burden due to schedule disruptions, caregiver mastery, KPS). Univariate Cox regression analyses were performed to examine the contribution of caregivers' depressive symptoms, anxiety, burden (3 subscales), and mastery on the survival time of patients with GBM. Significant associations at P < .10 between caregiver measures and patient survival were used to determine inclusion in a multivariable Cox regression analysis. Herein, other variables known to affect survival were included in the model: patient age, KPS, 38 postsurgical treatment (surgery only vs postsurgical chemotherapy vs postsurgical chemotherapy and radiotherapy), and extent of surgical resection (biopsy only vs surgical resection). Symptom severity and MGMT status were not added as covariates due to the large percentage of missing values; data regarding MGMT status were not routinely collected clinically during the first years of the study. Instead, Student t tests and chi-square tests were performed to check whether symptom severity and MGMT status were related to patient survival at 12 months (yes/no). For ease of interpretability, significant predictors of patient survival were divided into tertiles and multivariable Cox Original Article regression analyses including the aforementioned covariates were performed again. To illustrate the possible effects of data imputation, survival plots were generated for significant predictors of patient survival based on both the nonimputed data and the pooled imputed data. To examine whether demographic caregiver variables (age, sex, educational level [years of education], and relationship with patient [spouse or other]) were associated with the level of mastery, analysis of variance and chi-square tests were performed.
RESULTS
Participant Characteristics
In total, 88 caregiver-patient dyads were included in the current analyses (Table 1) . The majority of patients were men (64%) and the majority of caregivers were women (74%). Nearly 74% of dyads were in a spousal relationship. Consistent with the standard treatment protocol, 2 nearly 85% of patients received both postoperative chemotherapy and radiotherapy. Two cases were censored: 1 individual was still alive at the time of analyses (88 months since diagnosis) and another patient did not have a recorded date of death. The median overall survival for the sample was 14.5 months (range, 0-88 months; interquartile range, 14.75 months). Approximately one-half of the patients (46%) were still alive 12 months after the initial diagnosis. Table 2 shows disease-specific symptoms as reported by patients from baseline to 12 months. Although data were incomplete, there was no relationship noted between patients' baseline symptom severity (N 5 66) or MGMT methylation status (N 5 36) and survival at 12 months (all P > .05). Caregivers with and without data regarding caregiver burden (self-esteem and Univariate Cox regression revealed a significant association between self-esteem (caregiver burden) and patient survival, with a 7.9% increase in the probability of dying sooner (hazard) with each unit increase in caregiver selfesteem (95% confidence interval [95% CI], 0.99-1.18, based on 31 cases) ( Table 3 ). Caregiver mastery also was found to be associated with patient survival, with a 14% reduction in the probability of dying sooner (hazard) with each unit increase in mastery (95% CI, 0.79-0.93, based on 88 cases). When known covariates were used in multivariable models (adjusting for the patient's functional status [KPS], postsurgical treatment, type of surgery, and age), only the association between caregiver mastery and patient survival remained statistically significant. Each unit increase in caregiver mastery was associated with a 16.1% decreased hazard of patient death (95% CI, 0.77-0.91, based on 88 cases). Caregiver mastery was divided into tertiles (low, moderate, or high level of mastery) and plotted against patient survival probability, again adjusted for the patient's functional status (KPS), postsurgical treatment, type of surgery, and age, as shown in Figure 1 Top (nonimputed data; N 5 73) and Bottom (nonimputed data plus 5 rounds of imputation; pooled data, N 5 513). Moderate to high versus lower levels of caregiver mastery both appeared to be significantly associated with an extended patient survival time (moderate vs low: hazard ratio, 0.523; 95% CI, 0.30-0.90 [P 5 .020]; and high vs low: hazard ratio, 0.359; 95% CI, 0.20-0.65 [P 5 .001], based on 88 cases). No differences between groups of caregivers with low, moderate, or high levels of mastery and age, sex, educational level, or relationship with the patient were found (all P > .05). Table 4 shows patient treatment variables and survival in relation to caregiver mastery.
No statistically significant associations were found between the 2 other caregiver burden scales (abandonment and schedule disruptions), caregiver depression or caregiver anxiety, and survival of patients with GBM (P > .10).
DISCUSSION
To the best of our knowledge, the current study was a first attempt to examine the relationships between caregivers' emotional health and length of patient survival in neurooncology. Herein, we reported on patients newly diagnosed with GBM and their caregivers specifically, because these patients are a relatively uniform group. The majority of patients receive the same postsurgical treatment, and survival times generally range from 1 to 2 years after diagnosis. 2 Formal correction for MGMT methylation status, an important predictor of response to chemotherapy, 8 was not possible due to missing data. However, corrected for other variables known to influence survival in patients with GBM such as functional status (KPS), age, postsurgical treatment, and extent of surgical resection, significant effects of caregiver mastery on the probability of the patient dying sooner remained. Higher feelings of mastery were associated with a 16.1% risk reduction in the time to patient death.
Previous studies have suggested relationships between the mental health of caregivers and patients with cancer 40, 41 and, less often, between the physical functioning of caregivers and patients. 41, 42 To our knowledge, the theory that the emotional health of family caregivers could influence the physical functioning of patients with cancer and even their survival has been largely an assumption to date. A study in 100 patients with breast cancer hinted in this direction because distress within the marital relationship was found to influence patients' recovery and symptom severity, 43 and a small number of other studies have found that caregiver distress can influence the physical functioning of patients with cancer. [28] [29] [30] However, another recent, large study in patients with advanced cancer (484 patients) failed to demonstrate any specific effects of caregivers' mental health or self-efficacy (a construct similar to mastery) on the patients' physical health. 41 It should be noted that the studies described above did not include patient survival as an outcome. Regardless, it is possible that the neuro-oncology-specific situation, with its unique neurological and cognitive symptom pattern, rapid onset, and decline in patients' health, differs significantly from the general population of patients with cancer. Inconsistencies between what was found in the current analysis and reported in other studies underscore the need for further work in this area. Given that caregivers' feelings of mastery may influence the length of time to death in patients with GBM, it is vital to determine what constitutes mastery, and through which mechanisms this might influence patients' physical health. Although the results of the current study can neither confirm nor deny this, it appears plausible that caregivers who experience a high level of mastery may react more quickly to patients' physical needs (eg, through contacting health care professionals early in the case of a medical emergency, thus improving survival). Moreover, better mastery in caregivers could facilitate communication within the dyad, thereby leading to better mutual support, and through this mechanism influence patient health. However, this remains highly speculative because to our knowledge the literature in this area is sparse. We examined whether low, moderate, or high levels of mastery were related to caregiver age, sex, educational level, and the relationship with the patient, and found no statistically significant differences. In other patient populations, caregiver mastery has been associated with patient sex (better mastery when the patient is female) 44 and caregiver physical functioning (worse mastery with worse physical functioning). 45 In neuro-oncology, the patient's problem behavior is correlated with mastery. 21 Mastery is likely heavily interlinked with other determinants of caregivers' emotional health because low levels of mastery are known to influence depressive symptoms in neuro-oncology caregivers. 21 Therefore, it was unexpected that caregiver depression, anxiety, and burden were not found to be significantly associated with survival among patients with GBM in the current analyses.
The remarkably strong effects of mastery on patients' survival time noted in the current study could, in part, be explained by aspects of the patients' baseline functioning not covered by the covariates chosen for this analysis. We found no difference in symptom severity between patients who survived for <12 months or > 12 months, making this less likely to be an issue. Moreover, there may be unknown subgroups of patients within the sample in the current study because MGMT methylation status is known to influence the effectiveness of chemotherapy in patients with GBM. 8 Due to the recruitment period, we were unable to obtain reliable data regarding biomarkers for the majority of the study sample, but among 36 patients, MGMT status was not found to be related to patient survival at 12 months. Nevertheless, this remains a limitation of the current study. Finally, the results with regard to caregiver burden should be interpreted with caution because we had many missing values and the regression models were based on only 31 cases and 36 cases, respectively, for the self-esteem and abandonment scales, which is less than one-half of the total study sample. Indeed, univariate analysis yielded counterintuitive results for caregiver self-esteem that were significant at a level of P < .10 despite 1 (unity) being in the 95% CI. More complete data regarding caregiver burden might yield different results. It appears to be unlikely that incomplete assessments occurred as a result of burden because we used baseline caregiver assessments only. Comparisons between those who completed versus those who did not complete caregiver burden scales revealed no statistically significant difference with regard to demographic characteristics. Efforts currently are ongoing to replicate the current study with more complete data regarding MGMT methylation status to confirm or deny the results.
Regardless of these limitations, to the best of our knowledge the current study is the first to examine the potential impact of the emotional health of neuro-oncology family caregivers on patients' physical health outcomes. A randomized controlled trial demonstrated that feelings of mastery among caregivers of patients with high-grade glioma could be improved over a period of 8 months. 46 Other still currently ongoing intervention studies aimed at improving family caregivers' emotional health such as nurse-based and Web-based efforts such as SmartCare: Innovations in Caregiving Interventions (ClinicalTrials.-gov identifier NCT02058745; National Institutes of Health grant R01NR013170 [H.S.D. and P.R.S., principal investigators]) and Hold on, for each other (which is based on Acceptance and Commitment Therapy) 47 have included mastery and aspects of caregiver burden as outcome measures. Evaluating the outcome of these intervention studies on caregivers' emotional health and length of patient survival could help to explain some of these findings. Providing neuro-oncology caregivers with more structured support and guidance in clinical practice might be enough to empower them and lower their levels of distress, thus influencing patients' health for the better.
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